Hepatology — Find Specialists & Top Hospitals Worldwide | MyMedicPlus

Hepatology is the subspecialty of gastroenterology dedicated to the study, diagnosis, and management of diseases affecting the liver, gallbladder, biliary tract, and pancreas. The liver is the largest internal organ, performing over 500 essential physiological functions including protein synthesis, drug metabolism, bile production, clotting factor production, glycogen storage, and detoxification of ammonia and other toxins. Liver disease can therefore have profound consequences across virtually every organ system in the body.

Hepatologists are physicians who have completed gastroenterology training with additional focused subspecialty experience in advanced liver disease management. Transplant hepatologists have further training specifically in pre-transplant evaluation, post-transplant immunosuppression management, and recognition and treatment of transplant-specific complications such as graft rejection, biliary complications, and recurrent liver disease.

The scope of hepatology has been transformed over the past two decades by several major developments. The discovery and cure of hepatitis C infection using direct-acting antiviral (DAA) therapy — achieving greater than 95% sustained virological response (cure) in 8–12 weeks with oral medications — represents one of medicine's greatest recent success stories. Simultaneously, non-alcoholic fatty liver disease (NAFLD) and its progressive form metabolic-associated steatohepatitis (MASH, formerly NASH) have emerged as the leading cause of liver disease globally, driven by the obesity epidemic. Hepatocellular carcinoma (HCC) — primary liver cancer arising in cirrhotic liver — is one of the few cancers increasing in incidence worldwide, and hepatologists are central to its surveillance, diagnosis, and treatment within multidisciplinary oncology teams.

Transplant hepatology bridges clinical hepatology, transplant surgery, and critical care medicine. Liver transplantation offers curative treatment for end-stage liver disease and selected hepatocellular carcinoma, and hepatologists coordinate the complex pathway from referral through transplant listing, living donor evaluation, post-operative care, and lifelong immunosuppression management.

Hepatologists manage acute and chronic liver diseases across the full spectrum of severity:

• Chronic hepatitis B (CHB): Chronic infection with hepatitis B virus (HBV) causing progressive liver inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma risk; managed with antiviral suppression therapy (tenofovir, entecavir) and surveillance for liver cancer.
• Chronic hepatitis C (HCV): Blood-borne viral infection causing progressive liver fibrosis leading to cirrhosis and HCC; now curable in more than 95% of patients with 8–12 week courses of direct-acting antivirals (sofosbuvir-based regimens, glecaprevir-pibrentasvir).
• Non-alcoholic fatty liver disease (NAFLD) and metabolic-associated steatohepatitis (MASH): Fat accumulation in the liver associated with obesity, insulin resistance, and metabolic syndrome; MASH involves hepatic inflammation and can progress through fibrosis to cirrhosis and HCC in a significant minority of patients. Currently the most common liver disease globally.
• Alcoholic liver disease: Spectrum from alcoholic fatty liver (reversible) through alcoholic hepatitis (may be severe) to alcoholic cirrhosis; management requires alcohol abstinence, nutritional support, and treatment of complications.
• Autoimmune hepatitis (AIH): Immune-mediated hepatocellular damage characterised by elevated transaminases, elevated IgG, positive autoantibodies (ANA, SMA, anti-LKM1), and interface hepatitis on liver biopsy; treated with azathioprine and prednisolone long-term.
• Primary biliary cholangitis (PBC): Autoimmune destruction of intrahepatic bile ducts causing progressive cholestasis, pruritus, fatigue, and ultimately cirrhosis; positive AMA in over 90%; treated with ursodeoxycholic acid and obeticholic acid.
• Primary sclerosing cholangitis (PSC): Progressive inflammatory stricturing of the intra- and extrahepatic bile ducts, strongly associated with inflammatory bowel disease (especially ulcerative colitis); predisposes to cholangiocarcinoma; no effective medical therapy available.
• Cirrhosis: End-stage liver scarring from any chronic liver injury; complications include portal hypertension (ascites, oesophageal varices, spontaneous bacterial peritonitis), hepatic encephalopathy, hepatorenal syndrome, and hepatocellular carcinoma.
• Hepatocellular carcinoma (HCC): Primary liver cancer arising almost exclusively in a cirrhotic or chronically inflamed liver; treated with surgical resection, locoregional therapies (ablation, TACE, SIRT), or systemic therapy (sorafenib, atezolizumab-bevacizumab) depending on tumour stage and liver function.
• Wilson disease: Rare autosomal recessive copper metabolism disorder causing copper accumulation in the liver, brain, kidneys, and cornea (Kayser-Fleischer rings); presents in young adults with hepatitis, cirrhosis, or neuropsychiatric symptoms; treated with copper chelation (D-penicillamine, trientine) or zinc.
• Haemochromatosis: Genetic iron overload disorder (most commonly HFE-related) causing iron deposition in the liver, heart, pancreas, and joints; treated with regular therapeutic phlebotomy.
• Acute liver failure (ALF): Sudden severe hepatic dysfunction with coagulopathy and encephalopathy in a patient without prior liver disease; causes include paracetamol (acetaminophen) overdose, acute viral hepatitis, drug-induced liver injury, and Wilson disease; may require emergency liver transplantation.

Hepatologists use a range of diagnostic tests and therapeutic procedures specific to liver disease management:

• Liver function tests (LFTs) interpretation: Comprehensive assessment of ALT, AST (hepatocellular damage markers), ALP and GGT (cholestatic markers), bilirubin (conjugated and unconjugated), albumin (synthetic function), and INR/prothrombin time (clotting factor production) provides a window into the nature and severity of liver disease.
• Viral hepatitis serology and genotyping: HBsAg, anti-HBc, HBV DNA quantification, hepatitis C antibody, HCV RNA, and HCV genotyping guide antiviral treatment selection and monitoring for response.
• Liver biopsy (percutaneous and transjugular): Needle sampling of liver tissue for histopathological assessment of inflammation grade and fibrosis stage (Metavir F0–F4); transjugular biopsy is used when coagulopathy prevents the safer percutaneous approach.
• Transient elastography (FibroScan): Non-invasive measurement of liver stiffness using vibration-controlled transient elastography (VCTE) to estimate fibrosis stage without biopsy; increasingly preferred for monitoring disease progression in chronic liver diseases.
• Liver ultrasound with Doppler: First-line imaging for hepatic parenchymal assessment, biliary dilation, portal vein patency, ascites, and focal liver lesions; 6-monthly surveillance ultrasound plus AFP measurement is recommended for all cirrhotic patients to detect early HCC.
• Contrast-enhanced CT and MRI liver: Characterisation of focal liver lesions using dynamic imaging; the LI-RADS classification system using MRI with hepatobiliary contrast agents enables non-invasive HCC diagnosis in cirrhotic livers, often avoiding liver biopsy.
• Paracentesis (therapeutic and diagnostic): Needle drainage of ascites from the peritoneal cavity; diagnostic paracentesis analyses ascitic fluid for albumin, protein, cell count, and culture to diagnose or exclude spontaneous bacterial peritonitis (SBP); large-volume therapeutic paracentesis with concurrent albumin infusion relieves severe ascites.
• Transjugular intrahepatic portosystemic shunt (TIPS): Interventional radiology procedure creating a channel between the portal vein and hepatic vein using a metal stent to decompress portal hypertension; used to treat refractory ascites, recurrent variceal haemorrhage, and hepatorenal syndrome.
• Liver transplant evaluation: Comprehensive multidisciplinary assessment of cirrhotic patients for transplant listing, including cardiac evaluation, infection screening, social and psychological assessment, MELD score calculation, and discussion of living donor options.

Primary care physicians diagnose many liver conditions through routine blood testing, but specific situations warrant hepatology referral for specialist assessment and management.

Urgent hepatology evaluation is required for: jaundice (yellowing of skin and eyes) in an adult, which may represent acute hepatitis, biliary obstruction, or liver failure requiring rapid diagnosis; any suspicion of acute liver failure — characterised by jaundice, coagulopathy (INR above 1.5), and encephalopathy — is a medical emergency requiring immediate hospital admission and transplant centre involvement; significant haematemesis from suspected oesophageal varices requires emergency endoscopy and hepatology involvement; and rapid clinical deterioration in a known cirrhotic patient suggesting hepatic encephalopathy, spontaneous bacterial peritonitis, or hepatorenal syndrome.

Routine hepatology referral is appropriate for: a confirmed positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody test — specialist evaluation determines whether antiviral treatment is indicated and when to start surveillance; persistently elevated liver enzymes (ALT or AST above 2 times the upper limit of normal for more than 6 months) without an obvious cause; liver ultrasound showing cirrhosis, significant fatty change, or a focal liver lesion; confirmed or suspected cirrhosis for surveillance, complication management, and transplant assessment; and metabolic-associated steatohepatitis (MASH) with evidence of advanced fibrosis on elastography (FibroScan LSM above 8 kPa) or biopsy, where specialist input guides treatment escalation and monitoring intensity.

Hepatologists in the USA are gastroenterologists with subspecialty focus or formal fellowship training in liver disease. The training pathway begins with a 4-year medical degree (MD or DO), followed by a 3-year internal medicine residency and 2–3 year gastroenterology fellowship. Within gastroenterology fellowship, hepatology rotations provide exposure to liver clinic, hepatology consult service, and liver transplant medicine. Many gastroenterologists then pursue an additional 1–2 year hepatology or transplant hepatology fellowship for advanced subspecialty training.

Transplant hepatology is the only formally recognised subspecialty certification in hepatology in the USA — the American Board of Internal Medicine (ABIM) offers board certification in Transplant Hepatology requiring completion of a transplant hepatology fellowship at an ACGME-accredited programme and passing a dedicated subspecialty examination. Non-transplant hepatologists practise as gastroenterologists with hepatology interest, without a separate formal certification outside of transplant programmes.

In the UK, hepatology is an integrated component of the Gastroenterology and Hepatology CCT programme under the JRCPTB, with a formal hepatology subspecialty interest certificate available through the British Association for the Study of the Liver (BASL) and British Society of Gastroenterology (BSG). Transplant hepatologists work within designated liver transplant centres accredited by NHS England, requiring additional competency-based training in transplant medicine and immunosuppression management.

The rapidly evolving pharmaceutical landscape in hepatology — including new NASH treatments, next-generation antivirals for hepatitis B, and novel HCC systemic therapies — requires continuous professional development and active participation in specialist hepatology societies including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL).

Hepatology referral typically comes from a primary care physician or gastroenterologist based on abnormal liver function tests, positive viral hepatitis serology, or concerning imaging findings. Verify that your physician has gastroenterology training and, for liver transplant evaluation, seek a centre with a dedicated transplant programme. In the USA, liver transplant centres are regulated by UNOS (United Network for Organ Sharing) and must meet minimum volume and outcome standards.

For hepatitis C treatment — now a short, highly effective oral course — many patients can be managed by gastroenterologists with hepatology expertise or by primary care physicians in simplified treatment pathways, without requiring dedicated hepatology clinic attendance. However, cirrhotics, patients with prior treatment failure, and those with unusual genotypes benefit from specialist hepatology oversight.

For established cirrhosis, ongoing hepatologist care is essential for 6-monthly HCC surveillance (ultrasound + AFP), variceal screening by upper endoscopy, monitoring of liver synthetic function, and timely transplant listing before decompensation occurs. The MELD (Model for End-stage Liver Disease) score — calculated from INR, bilirubin, and creatinine — determines urgency for liver transplant listing in the USA.

For your first hepatology appointment, bring all recent liver blood tests (LFTs, clotting screen, full blood count), viral hepatitis serology results, liver imaging reports, FibroScan results if performed, and a complete medication list including over-the-counter drugs, herbal remedies, and dietary supplements — many of which are hepatotoxic and must be disclosed. Bring a clear alcohol history including type, quantity, and duration of use, as this critically affects diagnosis and treatment planning.